# A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

> **NCT05328557** · PHASE1 · COMPLETED · sponsor: **Cugene Inc.** · enrollment: 32 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** CUG252
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05328557
- **Lead sponsor:** Cugene Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-09
- **Primary completion:** 2022-08-03
- **Final completion:** 2022-08-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328557, "A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05328557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*